Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study

Autor: Hanna Johnsen, C. Christiansen, Lise Margrete Thomassen, Jens J. Holst, Mark Hvistendahl, Rahim M. Naimi, Bolette Hartmann, Palle Jeppesen

Publikováno v: BMJ Open Gastroenterology
BMJ Open Gastroenterology, Vol 8, Iss 1 (2021)
Naimi, R M, Hvistendahl, M K, Thomassen, L M, Johnsen, H, Christiansen, C B, Holst, J J, Hartmann, B & Jeppesen, P B 2021, ' Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity : an open-label pilot study ', BMJ Open Gastroenterology, vol. 8, no. 1, e000604 . https://doi.org/10.1136/bmjgast-2021-000604

ObjectivePatients with short bowel syndrome (SBS) and colon in continuity have better adaptation potential compared with patients with jejunostomy. Adaptation may involve enhanced postprandial secretion of the enteroendocrine hormones glucagon-like p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f59cddd4707f9b5a20fb2cb0839cc8a
https://pubmed.ncbi.nlm.nih.gov/33975891